AI Drug Discovery for Pharma and Biotech

Drug discovery

2

drugs

With orphan designations

Overview

Central serous chorioretinopathy (CSCR) is a chorioretinal disorder characterized by serous detachment of the neurosensory retina due to fluid leakage from choroidal hyperpermeability. Primarily affecting adults aged 20-50, it disproportionately affects males (6:1 ratio) and is associated with glucocorticoid use, stress, type A personality, and obstructive sleep apnea [1][4][12]. While 50-80% of acute cases resolve spontaneously within 3-4 months, 30-50% develop chronic/recurrent disease requiring intervention [4][6][16].

Population

  • Predominantly males (68-86% of cases) aged 28-60 years, peak incidence at 40-44 in men and 50-54 in women [2][7]

  • Higher prevalence in Asian and Hispanic populations compared to other ethnic groups [2][12]

  • Strong association with hypercortisolism: 5% of Cushing syndrome patients develop CSCR [4][12]

Burden

  • 30-50% recurrence rate with 14-35% developing permanent RPE atrophy [4][6][12]

  • Annual incidence: 34/100,000 person-years, costing $18M/year in US working-age adults [7][9]

  • 86% require no initial treatment, but 20% progress to chronic disease with reduced contrast sensitivity and metamorphopsia [7][18]

Therapies

  • First-line: Observation for acute cases (3-4 months) [1][3]

  • Chronic cases: Half-dose/half-fluence photodynamic therapy (PDT) shows 82% SRF resolution vs 26% with observation [1][3][13]

  • Adjunctive options: Focal laser for extrafoveal leaks, oral mineralocorticoid antagonists (eplerenone), anti-VEGF for CNV complications [1][3][15]

Categories: rare genetic diseases, rare ophthalmic disorders

Research Papers

1,247 drug discovery papers about Central serous chorioretinopathy, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

1,247 drug discovery papers about Central serous chorioretinopathy, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-28 | Stereopsis and Outer Retinal Structure After Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy: A 12-Month Study.

Changes in binocular function after anatomical resolution of central serous chorioretinopathy (CSC) following reduced-fluence photodynamic therapy (RFPDT) remain unclear. We characterized 12-month stereopsis outcomes and the associated clinical and optical coherence tomography (OCT) factors. This retrospective single-center study included 51 eyes of 51 patients with unilateral CSC treated with RFPDT. Best-corrected visual acuity (BCVA), Titmus Stereo Test (TST), TNO stereotest (TNO), and central retinal thickness (CRT) were assessed at baseline and at 3, 6, and 12 months. Stereopsis (TST and TNO) was the primary longitudinal outcome; BCVA and CRT were secondary. Change over time was assessed with linear mixed-effects models. Associations of baseline and concurrent clinical and OCT factors with stereopsis were examined using Spearman correlation and multivariable linear regression. Improvements in TST, TNO, and BCVA were evident by 3 months (all P < 0.001), with no significant further change thereafter except a small BCVA gain by 12 months (P = 0.006). At 12 months, abnormal stereopsis remained in 35% (TST) and 57% (TNO) of eyes. Larger baseline serous retinal detachment (SRD) area was independently associated with worse concurrent TST and TNO, but not with 12-month stereopsis. Greater 12-month outer retinal layer thickness (ORLT) was associated with better concurrent TNO in an adjusted model (P = 0.029). In eyes with good baseline acuity, longer baseline photoreceptor outer segment (POS) length was the only independent predictor of better 12-month TST. Stereopsis improved during the 12 months following RFPDT but often remained abnormal, even in eyes with good BCVA. Different structural parameters were associated with stereopsis by disease stage-subretinal fluid extent during active disease and residual outer retinal structure after resolution-and in these good-acuity eyes, pre-treatment outer retinal structure predicted 12-month stereopsis. Together, these findings suggest that stereopsis may capture residual visual dysfunction that is not fully reflected by BCVA.

Open article ↗



2026-09-16 | Microbiota-mitochondria axis in neurodegenerative disorders and retinal dysfunction: mechanisms and emerging therapeutic opportunities.

The gut microbiota crucial role in maintaining host metabolism, immune homeostasis, intestinal integrity, and mitochondrial function. Emerging evidence suggests that dysregulation of the microbiota-mitochondria axis represents one of the key mechanisms linking gut dysbiosis to the development of neurodegenerative and ocular diseases. The dysbiosis causes disruptions in mitochondrial physiology due to lower levels of short-chain fatty acids, increased intestinal permeability, endotoxemia, oxidative stress, and inflammation. These mechanisms contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and central serous chorioretinopathy. Environmental factors such as unhealthy dietary patterns, excessive antibiotic use, and prolonged exposure to artificial blue light may exacerbate dysbiosis and further disrupt mitochondrial homeostasis, thereby contributing to disease progression. We also elaborated the emerging therapeutic strategies targeting both the gut microbiota and mitochondrial function, including next-generation probiotics, postbiotics, dietary interventions, mitochondria-targeted antioxidants, NAD+ precursors, and precision medicine approaches. Collectively, current evidence represents the microbiota-mitochondria axis as a one of the promising mechanistic and therapeutic targets for neurodegenerative and ocular diseases. However, most therapeutic evidence discussed in this review is derived from preclinical studies, with relatively limited clinical validation. Future well-designed longitudinal studies and randomized clinical trials are essential to establish efficacy, safety, and translational applicability in humans.

Open article ↗



2026-09-11 | To determine the role of eplerenone as a treatment modality for chronic central serous chorioretinopathy – A case series

This case series was conducted to assess the role of eplerenone in the treatment of chronic Central serous chorioretinopathy (CSCR). This retrospective case series included patients with chronic CSCR who received oral eplerenone. Best-corrected visual acuity was recorded and converted to logMAR units. Spectral-domain optical coherence tomography was used to assess subretinal fluid (SRF) height and central macular thickness (CMT) at baseline and at 30 and 90 days during follow-up. Eight eyes from eight patients were included. All patients were male. Mean logMAR visual acuity improved from 0.3875 at baseline to 0.125 at 90 days. Mean CMT decreased from 451.38 mm to 293.38 mm, and mean SRF height decreased from 201.62 mm to 77.25 mm. A progressive reduction in SRF height and CMT was observed over the follow-up period, along with improvements in visual acuity. Oral eplerenone appears to be a beneficial therapeutic option in selected cases of chronic CSCR, particularly among young patients with central vision loss. Eplerenone may be considered for patients experiencing stress related to vision loss that disrupts their daily work activities.

Open article ↗



2026-08-27 | Steroid-Induced Central Serous Chorioretinopathy in Uveitis: Diagnostic Challenges and Multimodal Imaging with a Primary Inflammatory Choriocapillaropathy Illustrative Case.

Background and Clinical Significance. Steroid-induced central serous chorioretinopathy (CSCR) is a potential complication in patients with uveitis receiving corticosteroid therapy and may be misinterpreted as persistent inflammatory activity. Inflammatory and iatrogenic subretinal fluid may coexist, particularly in primary inflammatory choriocapillaropathies (PICCPs), creating diagnostic and therapeutic challenges. This narrative review discusses the pathophysiological mechanisms underlying steroid-induced CSCR and emphasizes the value of multimodal imaging in distinguishing inflammatory subretinal fluid from steroid-induced serous retinal detachment. Optical coherence tomography, fundus autofluorescence, fluorescein angiography and indocyanine green angiography provide complementary information that may guide accurate diagnosis and avoid inappropriate corticosteroid escalation. Case Presentation. An illustrative case of ampiginous choroiditis, a severe form of PICCP, complicated by bilateral steroid-induced CSCR shortly after initiation of high-dose corticosteroid therapy, is presented to highlight the clinical relevance of this complication and its therapeutic implications. Conclusions. Early recognition through multimodal imaging enabled prompt corticosteroid tapering and introduction of steroid-sparing immunosuppression, with subsequent marked anatomical and functional improvement.

Open article ↗



2026-08-25 | Pachychoroid diseases of the macula: an update.

The pachychoroid disease spectrum comprises a group of chorioretinal disorders characterized by structural and hemodynamic alterations of the choroid that may ultimately lead to dysfunction of the retinal pigment epithelium, choroidal neovascularization, and vision loss. This narrative review aims to summarize the recent advances in the understanding of pachychoroid spectrum diseases, with particular emphasis on pathophysiology, multimodal imaging, and current therapeutic approaches. Relevant English-language literature on pachychoroid spectrum disorders published up to 31 May 2026 was reviewed through PubMed/MEDLINE, supplemented by Google Scholar to identify additional relevant studies; relevant conference abstracts presented by that date and published subsequently were also included. Focus was on recent developments in disease mechanisms, imaging characteristics, clinical phenotypes, and management strategies. Search terms included "pachychoroid" and individual pachychoroid spectrum entities in combination with terms related to imaging, pathophysiology, diagnosis, and treatment. Relevant Medical Subject Headings (MeSH) terms were also used where applicable. Particular emphasis was placed on recently published studies reflecting current concepts and advances in pachychoroid disease. Earlier landmark studies with substantial scientific and historical relevance were additionally included to provide the original descriptions and foundational evidence underlying the pachychoroid spectrum. The pachychoroid spectrum is increasingly recognized as a continuum of disorders associated with choroidal vascular remodeling, venous congestion, and choriocapillaris attenuation. Characteristic multimodal imaging findings include pachyvessels, choroidal hyperpermeability, intervortex venous anastomoses, and variable inner choroidal thinning, while increased choroidal thickness alone may not reliably define the pachychoroid phenotype. Pachychoroid pigment epitheliopathy may occur as an isolated manifestation or coexist with other pachychoroid entities. Central serous chorioretinopathy represents a pivotal entity within the pachychoroid spectrum and may progress toward neovascular complications, including pachychoroid neovasculopathy and polypoidal choroidal vasculopathy. Advances in multimodal imaging, particularly optical coherence tomography angiography and ultra-widefield indocyanine green angiography, have substantially improved the detection of subclinical vascular alterations and disease progression. Although anti-vascular endothelial growth factor therapy and photodynamic therapy remain central treatment approaches, emerging modalities, including no-dose photodynamic therapy and photobiomodulation, are being investigated as potential therapeutic options, but current evidence does not support their routine clinical use. Pachychoroid spectrum disorders share common choroidal vascular and hemodynamic abnormalities despite considerable phenotypic variability. Ongoing advances in multimodal imaging and evolving therapeutic strategies continue to refine the understanding and management of these disorders.

Open article ↗



antibodies
2026-07-01 | Central Serous Chorioretinopathy: Current Concepts in Pathogenesis, Multimodal Imaging, and Management

Central serous chorioretinopathy (CSC) is a retinal disorder characterised by serous detachment of the neurosensory retina. It results from dysfunction of the retinal pigment epithelium and derangements in choroidal circulation. Once regarded as a benign and self-limiting macular disease of young men, CSC is now recognised as part of a broader pachychoroid spectrum in which choroidal vascular congestion, venous overload, and hyperpermeability play crucial roles. Multimodal imaging, including optical coherence tomography (OCT), fundus autofluorescence, indocyanine green angiography, and OCT-angiography, have significantly altered the understanding of this condition and allowed early identification of chronicity and complications such as choroidal neovascularisation. Management strategies continue to evolve. Although the availability of photodynamic therapy may be limited in some settings, micropulse laser, focal thermal laser, anti-vascular endothelial growth factor therapy, and selected systemic medications continue to have important roles in specific clinical scenarios. This narrative review provides an updated synthesis of current knowledge regarding CSC, emphasising its pathogenesis, clinical presentation, imaging findings, complications, and therapeutic approaches.

Open article ↗



2026-06-20 | Research advances in claudin-1 in the eye.

Claudin-1, a transmembrane protein integral to tight junctions, is indispensable for paracellular barrier formation and the establishment and maintenance of cellular polarity. In the eye, claudin-1 exhibits tissue-specific expression in critical structures such as the cornea and retina, where it contributes fundamentally to corneal transparency, blood-retinal barrier integrity, and retinal homeostasis. This review comprehensively synthesizes current knowledge on the spatial distribution and physiological roles of claudin-1 across ocular tissues. We critically evaluate recent mechanistic and translational advances implicating claudin-1 dysregulation in a spectrum of ocular pathologies: anterior segment disorders (dry eye disease, pterygium, infectious keratitis, and gelatinous drop-like corneal dystrophy), retinal diseases (diabetic retinopathy, age-related macular degeneration, central serous chorioretinopathy, and retinoblastoma), and other conditions (uveitis, glaucoma, post-cataract macular edema, and cataract). Finally, we assess the emerging therapeutic potential of claudin-1-both as a molecular target for barrier modulation and as a facilitator of paracellular drug delivery in ophthalmology.

Open article ↗



2026-06-02 | Evaluating the Correlation Between Optical Coherence Tomography Angiography-Derived Parameters and Serum Vascular Endothelial Growth Factor-A (VEGF-A) Levels in Central Serous Chorioretinopathy.

Release of vascular endothelial growth factor-A (VEGF-A) is one of the mechanisms involved in the pathogenesis of central serous chorioretinopathy (CSCR). We intended to evaluate the correlation between optical coherence tomography angiography (OCTA) parameters and serum VEGF-A levels in CSCR. Our prospective interventional study included 31 patients diagnosed with CSCR. The subjects had a mean age of 39.23±6.9 (26-53) years. They were examined for visual acuity (VA) and tested for color perception and contrast discrimination. OCT was conducted to examine central macular thickness (CMT) and subfoveal choroidal thickness (SFCT), and to detect neurosensory detachment (NSD), pigment epithelial detachment (PED), and other abnormalities. The OCTA measured foveal avascular zone (FAZ) and vessel density (VD) across various retino-choroidal layers. The serum VEGF-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The eyes were treated with a single intravitreal injection of 0.3 mg/0.05 ml ranibizumab biosimilar (RbB). After one month, the ocular parameters were rechecked, and serum VEGF-A levels were remeasured. We assessed the correlation between ocular parameters and VEGF-A levels in serum samples at both instances. At baseline, the mean value of the best corrected visual acuity (BCVA) in logarithm of the minimum angle of resolution (LogMAR) was 0.81±0.43. The CMT measured 286.81±117.67 microns, SFCT 194.32±62.76 microns, and the serum VEGF-A level was 351.64 (IQR 243.57-478.71) pg/ml. Before treatment, circulating VEGF-A levels correlated positively with the LogMAR value of BCVA (Rho=0.121), CMT (Rho=0.282), SFCT (Rho=0.006), NSD height (Rho=0.100) and width (Rho=0.019), and PED number (Rho=0.016), height (Rho=0.246) and width (Rho=0.066). The serum VEGF-A showed a weak positive correlation (p>0.05) with most OCTA features, whereas it correlated negatively with FAZ area (Rho=-0.136) and perimeter (Rho=-0.128). A month after intravitreal injection, LogMAR BCVA improved to 0.42±0.42, CMT measured 256.65±109.57 microns, and SFCT was 209.84±41.53 microns. The median serum VEGF-A level was 336.31 (IQR 259.455-500.105) pg/ml. Serum VEGF-A showed weak positive correlation with LogMAR value of BCVA (Rho=0.046), CMT (Rho=0.063), SFCT (Rho=0.094), NSD number (Rho=0.290), height (Rho=0.269) and width (Rho=0.289), and PED number (Rho=0.306), height (Rho=0.204) and width (Rho=0.124). The serum VEGF-A showed negative weak correlations (p>0.05) with OCTA features, including FAZ metrics --area (Rho=-0.156), perimeter (Rho=-0.114), and circularity (Rho=-0.335), as well as VD in various retino-choroidal layers: superficial capillary plexus (Rho=-0.282); deep capillary plexus (Rho=-0.225), outer retinal chorio-capillaries (Rho=-0.295), chorio-capillaries (Rho=-0.312) and choroid (Rho=-0.274). Higher serum VEGF-A was associated with worse VA and increased CMT, SFCT, NSD height and width, and PED number, height, and width. An increase in VEGF-A was related to reduced FAZ area and perimeter. At baseline, higher levels of VEGF-A were accompanied by an increase in VD in all layers except the outer retina and choroid. After treatment with intravitreal RbB, a similar pattern was observed; however, increased VEGF-A was found to be coupled with decreased VD in all retino-choroidal layers, except the outer retina.

Open article ↗



2026-05-27 | Effects of Selective Retina Therapy on Central Serous Chorioretinopathy with Serous Pigment Epithelial Detachments.

Background/Objective: This study's aim is to evaluate the anatomical and functional effects of selective retina therapy (SRT) in patients with central serous chorioretinopathy (CSC) accompanied by serous pigment epithelial detachment (PED). Methods: This retrospective study included 32 eyes from 32 patients with CSC and serous PED treated with SRT. Pulse energy and micropulse number were adjusted based on test spot visibility on fundus photographs. Best-corrected visual acuity (BCVA; logMAR), central foveal thickness (CFT), subretinal fluid (SRF) height, PED height, and subfoveal choroidal thickness were assessed at baseline and at 1, 2, and 3 months post-treatment. Retinal sensitivity was evaluated using microperimetry at baseline and 3 months. Results: At 3 months after SRT, complete SRF resolution was achieved in 78.1% of eyes (25/32). Mean BCVA improved significantly from 0.29 ± 0.30 logMAR at baseline to 0.20 ± 0.29 logMAR (p = 0.006). Mean CFT decreased from 284.7 ± 91.3 µm to 165.7 ± 94.8 µm (p < 0.001). Mean SRF height decreased from 150.5 ± 74.6 µm to 20.9 ± 48.3 µm (p < 0.001), and mean PED height decreased from 101.7 ± 96.9 µm to 33.3 ± 37.6 µm (p < 0.001). Retinal sensitivity showed a non-significant improvement at 3 months (p = 0.108). Reduction in PED height was moderately correlated with reduction in SRF height (r = 0.446, p = 0.011). Conclusions: SRT was associated with reductions in PED and SRF in CSC. These findings should be interpreted cautiously given the absence of a control group and the potential for spontaneous changes in SRF and PED.

Open article ↗



2026-05-27 | Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy).

To assess the long-term safety and efficacy of intravitreal brolucizumab (Pagenax®) in eyes with chronic central serous chorioretinopathy (CSC) complicated by neovascularization (pachychoroid neovasculopathy) refractory to prior therapies. In this single-center retrospective case series (January 2021-July 2025), 30 eyes of 25 patients with recalcitrant and refractory cases of chronic CSC with secondary neovascularization were treated off-label with pro-re-nata intravitreal brolucizumab. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and pigment epithelial detachment (PED) height were measured at baseline and 6 months, with extended outcomes in nine eyes assessed at 1 and 2 years. Adverse events were recorded at each visit. At 6 months, the mean CST decreased significantly from 328 ± 222 µm to 172 ± 79 µm ( P < 0.001), and the PED height declined from 262 ± 192 µm to 155 ± 123 µm ( P = 0.027). BCVA improved or remained stable in 90% of eyes, with no significant change in mean logMAR (0.38 to 0.33, P = 0.314). In the extended cohort, CST reductions persisted at 1 year (412 ± 241 µm to 271 ± 239 µm, P = 0.009) and 2 years (412 ± 241 µm to 164 ± 42 µm, P = 0.004), while BCVA stayed stable. A weak correlation suggested more injections might be linked to slightly poorer BCVA, possibly due to resistant cases requiring more treatment. No adverse events were noted. Intravitreal brolucizumab administered PRN effectively resolves persistent fluid and reduces PED in chronic CSC with PNV refractory to prior treatments, while maintaining stable visual acuity and demonstrating a favorable safety profile through 2 years of follow-up.

Open article ↗



gene therapies
2022-08-10 | An Insertion Variant in CRH Confers an Increased Risk of Central Serous Chorioretinopathy.

To identify a novel corticotropin-releasing hormone (CRH) gene variant relevant in patients with central serous chorioretinopathy (CSC). We performed a genetic study of CSC in families and sporadic cases with controls. Using whole-exome sequencing and linkage analysis, we identified a heterozygous insertion variant, Gln52insPro, in the CRH gene that cosegregated in two Chinese families with CSC. This variant was evaluated among an additional 1307 patients with CSC and 1438 ethnicity-matched control individuals from three independent Chinese cohorts. The CRH variant was strongly associated with CSC in these cohorts of Chinese patients (Pmeta = 1.24 × 10-11; odds ratio, 3.01; 95% confidence interval, 2.15-4.21). The risk variant Gln52insPro decreased CRH gene expression. Our results implicate the hypothalamic-pituitary-adrenal stress response system in the pathogenesis of CSC and provide a novel rationale for therapeutic intervention.

Open article ↗



2015-11-01 | Selective Retina Therapy

The safety and effectiveness of Selective Retina Therapy as a procedure that induces the regeneration of the retinal pigmented epithelial cells by selectively destroying only the retinal pigmented epithelial cell in patients with retinal diseases were assessed. Assessment was made on the Selective Retina Therapy by extending the range of patients to be subjected to this technology by including macular edema and central serous chorioretinopathy patients. Intervention procedures included a broad range of technologies that selectively damages the retinal pigments and all devices without limitation were selected in assessment of the safety and effectiveness of this technology. For information search, 8 domestic databases including Korea Med and overseas databases including Ovid-Medline, Ovid-Embase and Cochrane Library were used. A total of 55 relevant literatures were searched through the use of search words related to ‘selective retina therapy’. As the result, a total of 7 literatures were included in the final assessment by applying the criteria for selection and exclusion to the 28 literatures after having excluded 27 overlappingly searched literatures. Each of the stages from literature search to application of selection standards and extraction of data were carried out independently by 2 assessors under the deliberation by the Sub-committee. Although there is no safety problem with the Selective Retina Therapy when implemented on central serous chorioretinopathy patient, there is no literature that made report on the key effectiveness variable of the Therapy,making the assessment of the effectiveness of this technology difficulty. Therefore, this technology was assessed to be at a stage that requires further researches (Recommendation rating of D, Classification as technology in research stage i).

Open article ↗



2012-01-17 | Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina

Photoreceptors and retinal pigment epithelial cells (RPE) targeting remains challenging in ocular gene therapy. Viral gene transfer, the only method having reached clinical evaluation, still raises safety concerns when administered via subretinal injections. We have developed a novel transfection method in the adult rat, called suprachoroidal electrotransfer (ET), combining the administration of nonviral plasmid DNA into the suprachoroidal space with the application of an electrical field. Optimization of injection, electrical parameters and external electrodes geometry using a reporter plasmid, resulted in a large area of transfected tissues. Not only choroidal cells but also RPE, and potentially photoreceptors, were efficiently transduced for at least a month when using a cytomegalovirus (CMV) promoter. No ocular complications were recorded by angiographic, electroretinographic, and histological analyses, demonstrating that under selected conditions the procedure is devoid of side effects on the retina or the vasculature integrity. Moreover, a significant inhibition of laser induced-choroidal neovascularization (CNV) was achieved 15 days after transfection of a soluble vascular endothelial growth factor receptor-1 (sFlt-1)-encoding plasmid. This is the first nonviral gene transfer technique that is efficient for RPE targeting without inducing retinal detachment. This novel minimally invasive nonviral gene therapy method may open new prospects for human retinal therapies.

Open article ↗



cell therapies
2026-08-11 | Role of Circulating Immune Cells in Mediating the Effect of Gut Microbiota on Central Serous Chorioretinopathy: A Mendelian Randomization and Mediation Analysis.

Recent observational studies have revealed gut microbiota influences the development and progression of several retinal diseases. However, the causal relationship between gut microbiota and central serous chorioretinopathy (CSCR) are still not understood. The data of gut microbiota and circulating immune cell traits were identifed from large‑scale genome‑wide association studies (GWAS) summary data, and the data of CSCR come from FinnGen database.Mendelian randomization (MR) was used to investigate the causal relationships between gut microbiota, circulating immune cells, and CSCR. Mendelian randomization methods included inverse variance weighting and Bayesian weighting. Cochran's Q, Egger intercept, and MR-PRESSO were used to evaluate heterogeneity, genetic pleiotropy, and horizontal pleiotropy. Sensitivity was evaluated using leave-one-out method.Finally, we explored whether immune cell act as a mediating factor in the pathway from gut microbiota to CSCR. 12 gut microbiota traits were associated with increased genetic risk of CSCR, 2 were associated with decreased genetic risk of CSCR.Mediated mendelian randomization analysis identified 10 pathways through which gut microbiota affects the genetic prediction of CSCR through circulating immune cell mediation, with Demequinaceae via IgD-CD24-% lymphocyte (7.0%) and CD24 on sw mem (3.5%), Demequina via IgD-CD24-% lymphocyte (9.6%), GCA-900066575 sp900066385 via CD4 on CD28 + CD4+ (9.7%), Saccharofermentanaceae via CD45 on HLA DR+T cells (4.7%), CD80 on plasmacytoid DC (5.0%), and CD80 on CD62L + plasmacytoid DC (5.9%), UBA737 via HLA DR+CD8br AC (4.3%), CAG-1000 sp000434555 via Resting Treg% CD4 Treg (3.3%) affecting the genetic risk of CSCR. Our mediated mendelian randomization analysis provides genetic evidence suggesting that circulating immune cells may mediate the causal relationship between gut microbiota and CSCR. The identified associations and mediation effects offer new insights into potential therapeutic avenues for CSCR.

Open article ↗



2022-04-21 | Exploring the choroidal vascular labyrinth and its molecular and structural roles in health and disease.

The choroid is a key player in maintaining ocular homeostasis and plays a role in a variety of chorioretinal diseases, many of which are poorly understood. Recent advances in the field of single-cell RNA sequencing have yielded valuable insights into the properties of choroidal endothelial cells (CECs). Here, we review the role of the choroid in various physiological and pathophysiological mechanisms, focusing on the role of CECs. We also discuss new insights regarding the phenotypic properties of CECs, CEC subpopulations, and the value of measuring transcriptomics in primary CEC cultures derived from post-mortem eyes. In addition, we discuss key phenotypic, structural, and functional differences that distinguish CECs from other endothelial cells such as retinal vascular endothelial cells. Understanding the specific clinical and molecular properties of the choroid will shed new light on the pathogenesis of the broad clinical range of chorioretinal diseases such as age-related macular degeneration, central serous chorioretinopathy and other diseases within the pachychoroid spectrum, uveitis, and diabetic choroidopathy. Although our knowledge is still relatively limited with respect to the clinical features and molecular pathways that underlie these chorioretinal diseases, we summarise new approaches and discuss future directions for gaining new insights into these sight-threatening diseases and highlight new therapeutic strategies such as pluripotent stem cell‒based technologies and gene therapy.

Open article ↗



small molecules
2026-09-28 | Stereopsis and Outer Retinal Structure After Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy: A 12-Month Study.

Changes in binocular function after anatomical resolution of central serous chorioretinopathy (CSC) following reduced-fluence photodynamic therapy (RFPDT) remain unclear. We characterized 12-month stereopsis outcomes and the associated clinical and optical coherence tomography (OCT) factors. This retrospective single-center study included 51 eyes of 51 patients with unilateral CSC treated with RFPDT. Best-corrected visual acuity (BCVA), Titmus Stereo Test (TST), TNO stereotest (TNO), and central retinal thickness (CRT) were assessed at baseline and at 3, 6, and 12 months. Stereopsis (TST and TNO) was the primary longitudinal outcome; BCVA and CRT were secondary. Change over time was assessed with linear mixed-effects models. Associations of baseline and concurrent clinical and OCT factors with stereopsis were examined using Spearman correlation and multivariable linear regression. Improvements in TST, TNO, and BCVA were evident by 3 months (all P < 0.001), with no significant further change thereafter except a small BCVA gain by 12 months (P = 0.006). At 12 months, abnormal stereopsis remained in 35% (TST) and 57% (TNO) of eyes. Larger baseline serous retinal detachment (SRD) area was independently associated with worse concurrent TST and TNO, but not with 12-month stereopsis. Greater 12-month outer retinal layer thickness (ORLT) was associated with better concurrent TNO in an adjusted model (P = 0.029). In eyes with good baseline acuity, longer baseline photoreceptor outer segment (POS) length was the only independent predictor of better 12-month TST. Stereopsis improved during the 12 months following RFPDT but often remained abnormal, even in eyes with good BCVA. Different structural parameters were associated with stereopsis by disease stage-subretinal fluid extent during active disease and residual outer retinal structure after resolution-and in these good-acuity eyes, pre-treatment outer retinal structure predicted 12-month stereopsis. Together, these findings suggest that stereopsis may capture residual visual dysfunction that is not fully reflected by BCVA.

Open article ↗



2026-09-16 | Microbiota-mitochondria axis in neurodegenerative disorders and retinal dysfunction: mechanisms and emerging therapeutic opportunities.

The gut microbiota crucial role in maintaining host metabolism, immune homeostasis, intestinal integrity, and mitochondrial function. Emerging evidence suggests that dysregulation of the microbiota-mitochondria axis represents one of the key mechanisms linking gut dysbiosis to the development of neurodegenerative and ocular diseases. The dysbiosis causes disruptions in mitochondrial physiology due to lower levels of short-chain fatty acids, increased intestinal permeability, endotoxemia, oxidative stress, and inflammation. These mechanisms contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, and central serous chorioretinopathy. Environmental factors such as unhealthy dietary patterns, excessive antibiotic use, and prolonged exposure to artificial blue light may exacerbate dysbiosis and further disrupt mitochondrial homeostasis, thereby contributing to disease progression. We also elaborated the emerging therapeutic strategies targeting both the gut microbiota and mitochondrial function, including next-generation probiotics, postbiotics, dietary interventions, mitochondria-targeted antioxidants, NAD+ precursors, and precision medicine approaches. Collectively, current evidence represents the microbiota-mitochondria axis as a one of the promising mechanistic and therapeutic targets for neurodegenerative and ocular diseases. However, most therapeutic evidence discussed in this review is derived from preclinical studies, with relatively limited clinical validation. Future well-designed longitudinal studies and randomized clinical trials are essential to establish efficacy, safety, and translational applicability in humans.

Open article ↗



2026-09-11 | To determine the role of eplerenone as a treatment modality for chronic central serous chorioretinopathy – A case series

This case series was conducted to assess the role of eplerenone in the treatment of chronic Central serous chorioretinopathy (CSCR). This retrospective case series included patients with chronic CSCR who received oral eplerenone. Best-corrected visual acuity was recorded and converted to logMAR units. Spectral-domain optical coherence tomography was used to assess subretinal fluid (SRF) height and central macular thickness (CMT) at baseline and at 30 and 90 days during follow-up. Eight eyes from eight patients were included. All patients were male. Mean logMAR visual acuity improved from 0.3875 at baseline to 0.125 at 90 days. Mean CMT decreased from 451.38 mm to 293.38 mm, and mean SRF height decreased from 201.62 mm to 77.25 mm. A progressive reduction in SRF height and CMT was observed over the follow-up period, along with improvements in visual acuity. Oral eplerenone appears to be a beneficial therapeutic option in selected cases of chronic CSCR, particularly among young patients with central vision loss. Eplerenone may be considered for patients experiencing stress related to vision loss that disrupts their daily work activities.

Open article ↗



2026-08-27 | Steroid-Induced Central Serous Chorioretinopathy in Uveitis: Diagnostic Challenges and Multimodal Imaging with a Primary Inflammatory Choriocapillaropathy Illustrative Case.

Background and Clinical Significance. Steroid-induced central serous chorioretinopathy (CSCR) is a potential complication in patients with uveitis receiving corticosteroid therapy and may be misinterpreted as persistent inflammatory activity. Inflammatory and iatrogenic subretinal fluid may coexist, particularly in primary inflammatory choriocapillaropathies (PICCPs), creating diagnostic and therapeutic challenges. This narrative review discusses the pathophysiological mechanisms underlying steroid-induced CSCR and emphasizes the value of multimodal imaging in distinguishing inflammatory subretinal fluid from steroid-induced serous retinal detachment. Optical coherence tomography, fundus autofluorescence, fluorescein angiography and indocyanine green angiography provide complementary information that may guide accurate diagnosis and avoid inappropriate corticosteroid escalation. Case Presentation. An illustrative case of ampiginous choroiditis, a severe form of PICCP, complicated by bilateral steroid-induced CSCR shortly after initiation of high-dose corticosteroid therapy, is presented to highlight the clinical relevance of this complication and its therapeutic implications. Conclusions. Early recognition through multimodal imaging enabled prompt corticosteroid tapering and introduction of steroid-sparing immunosuppression, with subsequent marked anatomical and functional improvement.

Open article ↗



2026-08-25 | Pachychoroid diseases of the macula: an update.

The pachychoroid disease spectrum comprises a group of chorioretinal disorders characterized by structural and hemodynamic alterations of the choroid that may ultimately lead to dysfunction of the retinal pigment epithelium, choroidal neovascularization, and vision loss. This narrative review aims to summarize the recent advances in the understanding of pachychoroid spectrum diseases, with particular emphasis on pathophysiology, multimodal imaging, and current therapeutic approaches. Relevant English-language literature on pachychoroid spectrum disorders published up to 31 May 2026 was reviewed through PubMed/MEDLINE, supplemented by Google Scholar to identify additional relevant studies; relevant conference abstracts presented by that date and published subsequently were also included. Focus was on recent developments in disease mechanisms, imaging characteristics, clinical phenotypes, and management strategies. Search terms included "pachychoroid" and individual pachychoroid spectrum entities in combination with terms related to imaging, pathophysiology, diagnosis, and treatment. Relevant Medical Subject Headings (MeSH) terms were also used where applicable. Particular emphasis was placed on recently published studies reflecting current concepts and advances in pachychoroid disease. Earlier landmark studies with substantial scientific and historical relevance were additionally included to provide the original descriptions and foundational evidence underlying the pachychoroid spectrum. The pachychoroid spectrum is increasingly recognized as a continuum of disorders associated with choroidal vascular remodeling, venous congestion, and choriocapillaris attenuation. Characteristic multimodal imaging findings include pachyvessels, choroidal hyperpermeability, intervortex venous anastomoses, and variable inner choroidal thinning, while increased choroidal thickness alone may not reliably define the pachychoroid phenotype. Pachychoroid pigment epitheliopathy may occur as an isolated manifestation or coexist with other pachychoroid entities. Central serous chorioretinopathy represents a pivotal entity within the pachychoroid spectrum and may progress toward neovascular complications, including pachychoroid neovasculopathy and polypoidal choroidal vasculopathy. Advances in multimodal imaging, particularly optical coherence tomography angiography and ultra-widefield indocyanine green angiography, have substantially improved the detection of subclinical vascular alterations and disease progression. Although anti-vascular endothelial growth factor therapy and photodynamic therapy remain central treatment approaches, emerging modalities, including no-dose photodynamic therapy and photobiomodulation, are being investigated as potential therapeutic options, but current evidence does not support their routine clinical use. Pachychoroid spectrum disorders share common choroidal vascular and hemodynamic abnormalities despite considerable phenotypic variability. Ongoing advances in multimodal imaging and evolving therapeutic strategies continue to refine the understanding and management of these disorders.

Open article ↗



antibodies
2026-07-01 | Central Serous Chorioretinopathy: Current Concepts in Pathogenesis, Multimodal Imaging, and Management

Central serous chorioretinopathy (CSC) is a retinal disorder characterised by serous detachment of the neurosensory retina. It results from dysfunction of the retinal pigment epithelium and derangements in choroidal circulation. Once regarded as a benign and self-limiting macular disease of young men, CSC is now recognised as part of a broader pachychoroid spectrum in which choroidal vascular congestion, venous overload, and hyperpermeability play crucial roles. Multimodal imaging, including optical coherence tomography (OCT), fundus autofluorescence, indocyanine green angiography, and OCT-angiography, have significantly altered the understanding of this condition and allowed early identification of chronicity and complications such as choroidal neovascularisation. Management strategies continue to evolve. Although the availability of photodynamic therapy may be limited in some settings, micropulse laser, focal thermal laser, anti-vascular endothelial growth factor therapy, and selected systemic medications continue to have important roles in specific clinical scenarios. This narrative review provides an updated synthesis of current knowledge regarding CSC, emphasising its pathogenesis, clinical presentation, imaging findings, complications, and therapeutic approaches.

Open article ↗



2026-06-20 | Research advances in claudin-1 in the eye.

Claudin-1, a transmembrane protein integral to tight junctions, is indispensable for paracellular barrier formation and the establishment and maintenance of cellular polarity. In the eye, claudin-1 exhibits tissue-specific expression in critical structures such as the cornea and retina, where it contributes fundamentally to corneal transparency, blood-retinal barrier integrity, and retinal homeostasis. This review comprehensively synthesizes current knowledge on the spatial distribution and physiological roles of claudin-1 across ocular tissues. We critically evaluate recent mechanistic and translational advances implicating claudin-1 dysregulation in a spectrum of ocular pathologies: anterior segment disorders (dry eye disease, pterygium, infectious keratitis, and gelatinous drop-like corneal dystrophy), retinal diseases (diabetic retinopathy, age-related macular degeneration, central serous chorioretinopathy, and retinoblastoma), and other conditions (uveitis, glaucoma, post-cataract macular edema, and cataract). Finally, we assess the emerging therapeutic potential of claudin-1-both as a molecular target for barrier modulation and as a facilitator of paracellular drug delivery in ophthalmology.

Open article ↗



2026-06-02 | Evaluating the Correlation Between Optical Coherence Tomography Angiography-Derived Parameters and Serum Vascular Endothelial Growth Factor-A (VEGF-A) Levels in Central Serous Chorioretinopathy.

Release of vascular endothelial growth factor-A (VEGF-A) is one of the mechanisms involved in the pathogenesis of central serous chorioretinopathy (CSCR). We intended to evaluate the correlation between optical coherence tomography angiography (OCTA) parameters and serum VEGF-A levels in CSCR. Our prospective interventional study included 31 patients diagnosed with CSCR. The subjects had a mean age of 39.23±6.9 (26-53) years. They were examined for visual acuity (VA) and tested for color perception and contrast discrimination. OCT was conducted to examine central macular thickness (CMT) and subfoveal choroidal thickness (SFCT), and to detect neurosensory detachment (NSD), pigment epithelial detachment (PED), and other abnormalities. The OCTA measured foveal avascular zone (FAZ) and vessel density (VD) across various retino-choroidal layers. The serum VEGF-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The eyes were treated with a single intravitreal injection of 0.3 mg/0.05 ml ranibizumab biosimilar (RbB). After one month, the ocular parameters were rechecked, and serum VEGF-A levels were remeasured. We assessed the correlation between ocular parameters and VEGF-A levels in serum samples at both instances. At baseline, the mean value of the best corrected visual acuity (BCVA) in logarithm of the minimum angle of resolution (LogMAR) was 0.81±0.43. The CMT measured 286.81±117.67 microns, SFCT 194.32±62.76 microns, and the serum VEGF-A level was 351.64 (IQR 243.57-478.71) pg/ml. Before treatment, circulating VEGF-A levels correlated positively with the LogMAR value of BCVA (Rho=0.121), CMT (Rho=0.282), SFCT (Rho=0.006), NSD height (Rho=0.100) and width (Rho=0.019), and PED number (Rho=0.016), height (Rho=0.246) and width (Rho=0.066). The serum VEGF-A showed a weak positive correlation (p>0.05) with most OCTA features, whereas it correlated negatively with FAZ area (Rho=-0.136) and perimeter (Rho=-0.128). A month after intravitreal injection, LogMAR BCVA improved to 0.42±0.42, CMT measured 256.65±109.57 microns, and SFCT was 209.84±41.53 microns. The median serum VEGF-A level was 336.31 (IQR 259.455-500.105) pg/ml. Serum VEGF-A showed weak positive correlation with LogMAR value of BCVA (Rho=0.046), CMT (Rho=0.063), SFCT (Rho=0.094), NSD number (Rho=0.290), height (Rho=0.269) and width (Rho=0.289), and PED number (Rho=0.306), height (Rho=0.204) and width (Rho=0.124). The serum VEGF-A showed negative weak correlations (p>0.05) with OCTA features, including FAZ metrics --area (Rho=-0.156), perimeter (Rho=-0.114), and circularity (Rho=-0.335), as well as VD in various retino-choroidal layers: superficial capillary plexus (Rho=-0.282); deep capillary plexus (Rho=-0.225), outer retinal chorio-capillaries (Rho=-0.295), chorio-capillaries (Rho=-0.312) and choroid (Rho=-0.274). Higher serum VEGF-A was associated with worse VA and increased CMT, SFCT, NSD height and width, and PED number, height, and width. An increase in VEGF-A was related to reduced FAZ area and perimeter. At baseline, higher levels of VEGF-A were accompanied by an increase in VD in all layers except the outer retina and choroid. After treatment with intravitreal RbB, a similar pattern was observed; however, increased VEGF-A was found to be coupled with decreased VD in all retino-choroidal layers, except the outer retina.

Open article ↗



2026-05-27 | Effects of Selective Retina Therapy on Central Serous Chorioretinopathy with Serous Pigment Epithelial Detachments.

Background/Objective: This study's aim is to evaluate the anatomical and functional effects of selective retina therapy (SRT) in patients with central serous chorioretinopathy (CSC) accompanied by serous pigment epithelial detachment (PED). Methods: This retrospective study included 32 eyes from 32 patients with CSC and serous PED treated with SRT. Pulse energy and micropulse number were adjusted based on test spot visibility on fundus photographs. Best-corrected visual acuity (BCVA; logMAR), central foveal thickness (CFT), subretinal fluid (SRF) height, PED height, and subfoveal choroidal thickness were assessed at baseline and at 1, 2, and 3 months post-treatment. Retinal sensitivity was evaluated using microperimetry at baseline and 3 months. Results: At 3 months after SRT, complete SRF resolution was achieved in 78.1% of eyes (25/32). Mean BCVA improved significantly from 0.29 ± 0.30 logMAR at baseline to 0.20 ± 0.29 logMAR (p = 0.006). Mean CFT decreased from 284.7 ± 91.3 µm to 165.7 ± 94.8 µm (p < 0.001). Mean SRF height decreased from 150.5 ± 74.6 µm to 20.9 ± 48.3 µm (p < 0.001), and mean PED height decreased from 101.7 ± 96.9 µm to 33.3 ± 37.6 µm (p < 0.001). Retinal sensitivity showed a non-significant improvement at 3 months (p = 0.108). Reduction in PED height was moderately correlated with reduction in SRF height (r = 0.446, p = 0.011). Conclusions: SRT was associated with reductions in PED and SRF in CSC. These findings should be interpreted cautiously given the absence of a control group and the potential for spontaneous changes in SRF and PED.

Open article ↗



2026-05-27 | Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy).

To assess the long-term safety and efficacy of intravitreal brolucizumab (Pagenax®) in eyes with chronic central serous chorioretinopathy (CSC) complicated by neovascularization (pachychoroid neovasculopathy) refractory to prior therapies. In this single-center retrospective case series (January 2021-July 2025), 30 eyes of 25 patients with recalcitrant and refractory cases of chronic CSC with secondary neovascularization were treated off-label with pro-re-nata intravitreal brolucizumab. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and pigment epithelial detachment (PED) height were measured at baseline and 6 months, with extended outcomes in nine eyes assessed at 1 and 2 years. Adverse events were recorded at each visit. At 6 months, the mean CST decreased significantly from 328 ± 222 µm to 172 ± 79 µm ( P < 0.001), and the PED height declined from 262 ± 192 µm to 155 ± 123 µm ( P = 0.027). BCVA improved or remained stable in 90% of eyes, with no significant change in mean logMAR (0.38 to 0.33, P = 0.314). In the extended cohort, CST reductions persisted at 1 year (412 ± 241 µm to 271 ± 239 µm, P = 0.009) and 2 years (412 ± 241 µm to 164 ± 42 µm, P = 0.004), while BCVA stayed stable. A weak correlation suggested more injections might be linked to slightly poorer BCVA, possibly due to resistant cases requiring more treatment. No adverse events were noted. Intravitreal brolucizumab administered PRN effectively resolves persistent fluid and reduces PED in chronic CSC with PNV refractory to prior treatments, while maintaining stable visual acuity and demonstrating a favorable safety profile through 2 years of follow-up.

Open article ↗



gene therapies
2022-08-10 | An Insertion Variant in CRH Confers an Increased Risk of Central Serous Chorioretinopathy.

To identify a novel corticotropin-releasing hormone (CRH) gene variant relevant in patients with central serous chorioretinopathy (CSC). We performed a genetic study of CSC in families and sporadic cases with controls. Using whole-exome sequencing and linkage analysis, we identified a heterozygous insertion variant, Gln52insPro, in the CRH gene that cosegregated in two Chinese families with CSC. This variant was evaluated among an additional 1307 patients with CSC and 1438 ethnicity-matched control individuals from three independent Chinese cohorts. The CRH variant was strongly associated with CSC in these cohorts of Chinese patients (Pmeta = 1.24 × 10-11; odds ratio, 3.01; 95% confidence interval, 2.15-4.21). The risk variant Gln52insPro decreased CRH gene expression. Our results implicate the hypothalamic-pituitary-adrenal stress response system in the pathogenesis of CSC and provide a novel rationale for therapeutic intervention.

Open article ↗



2015-11-01 | Selective Retina Therapy

The safety and effectiveness of Selective Retina Therapy as a procedure that induces the regeneration of the retinal pigmented epithelial cells by selectively destroying only the retinal pigmented epithelial cell in patients with retinal diseases were assessed. Assessment was made on the Selective Retina Therapy by extending the range of patients to be subjected to this technology by including macular edema and central serous chorioretinopathy patients. Intervention procedures included a broad range of technologies that selectively damages the retinal pigments and all devices without limitation were selected in assessment of the safety and effectiveness of this technology. For information search, 8 domestic databases including Korea Med and overseas databases including Ovid-Medline, Ovid-Embase and Cochrane Library were used. A total of 55 relevant literatures were searched through the use of search words related to ‘selective retina therapy’. As the result, a total of 7 literatures were included in the final assessment by applying the criteria for selection and exclusion to the 28 literatures after having excluded 27 overlappingly searched literatures. Each of the stages from literature search to application of selection standards and extraction of data were carried out independently by 2 assessors under the deliberation by the Sub-committee. Although there is no safety problem with the Selective Retina Therapy when implemented on central serous chorioretinopathy patient, there is no literature that made report on the key effectiveness variable of the Therapy,making the assessment of the effectiveness of this technology difficulty. Therefore, this technology was assessed to be at a stage that requires further researches (Recommendation rating of D, Classification as technology in research stage i).

Open article ↗



2012-01-17 | Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina

Photoreceptors and retinal pigment epithelial cells (RPE) targeting remains challenging in ocular gene therapy. Viral gene transfer, the only method having reached clinical evaluation, still raises safety concerns when administered via subretinal injections. We have developed a novel transfection method in the adult rat, called suprachoroidal electrotransfer (ET), combining the administration of nonviral plasmid DNA into the suprachoroidal space with the application of an electrical field. Optimization of injection, electrical parameters and external electrodes geometry using a reporter plasmid, resulted in a large area of transfected tissues. Not only choroidal cells but also RPE, and potentially photoreceptors, were efficiently transduced for at least a month when using a cytomegalovirus (CMV) promoter. No ocular complications were recorded by angiographic, electroretinographic, and histological analyses, demonstrating that under selected conditions the procedure is devoid of side effects on the retina or the vasculature integrity. Moreover, a significant inhibition of laser induced-choroidal neovascularization (CNV) was achieved 15 days after transfection of a soluble vascular endothelial growth factor receptor-1 (sFlt-1)-encoding plasmid. This is the first nonviral gene transfer technique that is efficient for RPE targeting without inducing retinal detachment. This novel minimally invasive nonviral gene therapy method may open new prospects for human retinal therapies.

Open article ↗



cell therapies
2026-08-11 | Role of Circulating Immune Cells in Mediating the Effect of Gut Microbiota on Central Serous Chorioretinopathy: A Mendelian Randomization and Mediation Analysis.

Recent observational studies have revealed gut microbiota influences the development and progression of several retinal diseases. However, the causal relationship between gut microbiota and central serous chorioretinopathy (CSCR) are still not understood. The data of gut microbiota and circulating immune cell traits were identifed from large‑scale genome‑wide association studies (GWAS) summary data, and the data of CSCR come from FinnGen database.Mendelian randomization (MR) was used to investigate the causal relationships between gut microbiota, circulating immune cells, and CSCR. Mendelian randomization methods included inverse variance weighting and Bayesian weighting. Cochran's Q, Egger intercept, and MR-PRESSO were used to evaluate heterogeneity, genetic pleiotropy, and horizontal pleiotropy. Sensitivity was evaluated using leave-one-out method.Finally, we explored whether immune cell act as a mediating factor in the pathway from gut microbiota to CSCR. 12 gut microbiota traits were associated with increased genetic risk of CSCR, 2 were associated with decreased genetic risk of CSCR.Mediated mendelian randomization analysis identified 10 pathways through which gut microbiota affects the genetic prediction of CSCR through circulating immune cell mediation, with Demequinaceae via IgD-CD24-% lymphocyte (7.0%) and CD24 on sw mem (3.5%), Demequina via IgD-CD24-% lymphocyte (9.6%), GCA-900066575 sp900066385 via CD4 on CD28 + CD4+ (9.7%), Saccharofermentanaceae via CD45 on HLA DR+T cells (4.7%), CD80 on plasmacytoid DC (5.0%), and CD80 on CD62L + plasmacytoid DC (5.9%), UBA737 via HLA DR+CD8br AC (4.3%), CAG-1000 sp000434555 via Resting Treg% CD4 Treg (3.3%) affecting the genetic risk of CSCR. Our mediated mendelian randomization analysis provides genetic evidence suggesting that circulating immune cells may mediate the causal relationship between gut microbiota and CSCR. The identified associations and mediation effects offer new insights into potential therapeutic avenues for CSCR.

Open article ↗



2022-04-21 | Exploring the choroidal vascular labyrinth and its molecular and structural roles in health and disease.

The choroid is a key player in maintaining ocular homeostasis and plays a role in a variety of chorioretinal diseases, many of which are poorly understood. Recent advances in the field of single-cell RNA sequencing have yielded valuable insights into the properties of choroidal endothelial cells (CECs). Here, we review the role of the choroid in various physiological and pathophysiological mechanisms, focusing on the role of CECs. We also discuss new insights regarding the phenotypic properties of CECs, CEC subpopulations, and the value of measuring transcriptomics in primary CEC cultures derived from post-mortem eyes. In addition, we discuss key phenotypic, structural, and functional differences that distinguish CECs from other endothelial cells such as retinal vascular endothelial cells. Understanding the specific clinical and molecular properties of the choroid will shed new light on the pathogenesis of the broad clinical range of chorioretinal diseases such as age-related macular degeneration, central serous chorioretinopathy and other diseases within the pachychoroid spectrum, uveitis, and diabetic choroidopathy. Although our knowledge is still relatively limited with respect to the clinical features and molecular pathways that underlie these chorioretinal diseases, we summarise new approaches and discuss future directions for gaining new insights into these sight-threatening diseases and highlight new therapeutic strategies such as pluripotent stem cell‒based technologies and gene therapy.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

2 orphan drug designations for Central serous chorioretinopathy.

2 orphan drug designations for Central serous chorioretinopathy.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Spironolactone

small molecules

EMA
2026-01-09

—

Dan Mejlachowicz

verteporfin

small molecules

FDA
2012-03-09

Phase II
Terminated

Valeant Pharmaceuticals North America LLC

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.